Significance of tyrosine kinase inhibitors in the treatment of metastatic breast cancer

Breast Care

Volumn 4, Issue 6, 2009, Pages 373-378

  Mundhenke, Christoph ^a   Strauss, Alexander ^a   Schem, Christian ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Anti angiogenesis; Her 2 neu; Intracellular kinase pathways; Metastatic breast cancer; Tyrosine kinase inhibitor

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; ANASTROZOLE; AXITINIB; CAPECITABINE; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; IMATINIB; LAPATINIB; LETROZOLE; NAVELBINE; PACLITAXEL; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN RECEPTOR;

ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER FUNCTION; LOADING DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 76749132497     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000261705     Document Type: Review

References (18)

1. Blackwell KL, Pegram ML, Tan-Chiu E, et al.: Single- agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 2009;20:1026-1031.
2. Kaufman B, Trudeau M, Awada A, et al.: Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 2009;10:581-588.
3. Lin NU, Diéras V, Pau D, et al.: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-1459.
4. Geyer CE, Forster J, Lindquist D, et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
5. Cameron D, Casey M, Press M, Lindquist D, et al.: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-543.
6. Di Leo A, Gomez H, Aziz Z, Zvirbule Z, et al.: Lapatinib with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, doubleblind study of 580 patients. J Clin Oncol 2007, ASCO Annual Meeting, Abstract #1011 (No.18S).
7. Storniolo AM, Pegram MD, Overmoyer B, Silverman P, Peacock NW, et al.: Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2008; 26:3317-3323.
8. Swaby R, Blackwell K, Jiang Z, Sun Y: Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study. J Clin Oncol 2009, ASCO Annual Meeting, Abstract #1004.
9. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, et al.: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5492-5494.
10. Cristofanilli M, Valero V, Mangalik A, Rabinowitz I, et al.: A phase II multicenter, double blind, randomized trial to compare anastrozole plus gefitinib with anastrazole plus placebo in postmenopausal women with hormone receptor positive metastatic breast cancer. J Clin Oncol 2008, ASCO Annual Meeting, Abstract #1012 (44S).
11. Burstein HJ, Elias AD, Rugo HS, et al.: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-1816.
12. Gianni L, Cardoso F, Mariani G, et al.: Exploratory evaluation of sequential administration of docetaxel and sunitinib in women with advanced breast cancer. SABCS 2007. Breast Cancer Res Treat 2007;106(suppl 1):273.
13. Kozloff M, et al.: A phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer: preliminary results. SABCS 2007. Breast Cancer Res Treat 2007;106(suppl 1):273.
14. Hutson T, Davis I, Machiels J, de Souza P, et al.: Pazopanib (GW786034) is active in metastatic renal cell carcinoma: interim results of a phase II randomized discontinuation trial. J Clin Oncol 2007, ASCO Annual Meeting, Abstract #5031.
15. Slamon D, Gomez H, Kabbinavar F, Amit O, et al.: Randomized study of pazopanib + lapatinib vs lapatinib alone in patients with HER2 positive advanced or metastatic breast cancer. J Clin Oncol 2008, ASCO Annual Meeting, Abstract #1016 (45S).
16. Rugo H, Stopeck A, Joy A, Chan S, et al.: A randomized, double blind phase II study of the oral tyrosine kinase inhibitor axitinib (AG013736) in combination with docetaxel compared to docetaxel plus placebo in metastatic breast cancer. J Clin Oncol 2007, ASCO Annual Meeting, Abstract #1003 (18S).
17. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, et al.: Imatinib mesylate (Gleevec) in advanced breast cancer-expressing c-kit or PDGFR-β: clinical activity and biological correlations. Ann Oncol 2008;19:1713-1719.
18. Weigel MT, Meinhold-Heerlein I, Maass N, Mundhenke C, et al.: Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR βsignalling. Cancer Lett 2009;273:70-79.